Press release 2009-10-28

 
C-RAD AB with its three fully owned subsidiaries
is all active in the field of
radiation therapy. C-RAD Imaging AB and IBA
Dosimetry  have signed a letter of
intent to develop and adapt the GEMini
system to be integrated in the dosimetry
program sold by IBA. 

The intent
is, based on an agreed upon specification and time schedule , to
develop a
transparent radiation detector, based on the C-RAD GEMini technology.
For this
application the C-RAD GEMini technology is offering high resolution,
low
attenuation and high radiation resistance. 

The GEMini TD detector is
planned to be part of the IBA solution to verify the
actual dose delivered to
patients during treatment. IBA Dosimetry is the
recognized world leader in
radiation therapy dosimetry and has a.o. strategic
cooperations with the
Swedish company RaySearch Laboratories AB. 

The parties have the intention
to sign an agreement not later than 31 December
2009. In parallel with
negotiations technical performances will be evaluated by
the parties. 

Erik
Hedlund, CEO, C-RAD AB:

" The IBA main requirements for a transparent 
radiation detector are
challenging but can with the unique C-RAD GEMini
technology be offered. The
system will be compatible with the modern treatment
technologies and contribute
to an even more efficient and accurate patient
treatment.” 

For further information: 

Erik Hedlund, CEO C-RAD AB,
Telefon 018 - 66 69 31, E-post erik.hedlund@c-rad.se

 

 

 

 





ABOUT  IBA

Founded in 1986 in Louvain-la-Neuve, Belgium, IBA is
primarily active in the
medical industry. It 

develops and markets
state-of-the-art equipment and radiopharmaceuticals for
cancer diagnosis and


treatment. In addition, it uses the scientific expertise thus gained to
provide
electron accelerators for 

industrial sterilization and ionization.
Listed on the pan-European stock
exchange Euronext, IBA is 

included in the
BEL Mid Index (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

Website:
http://www.iba-worldwide.com